argenex SE (NASDAQ:ARGX) Stock Has Consensus Target Price of $1,145.00

Shares of argenex SE (NASDAQ:ARGX) have received a consensus recommendation of “Moderate Buy” from the twenty-eight research firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, twenty-one have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $1,158.76.

Several equities analysts have recently issued reports on the stock. Barclays reaffirmed a “buy” rating on shares of argenex in a research note on Monday, September 7th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a report on Wednesday, October 21st. The Goldman Sachs Group reaffirmed a “buy” rating on shares of argenex in a research report on Friday, September 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of argenex in a report on Monday, September 14th. Finally, UBS Group upgraded argenex from a “neutral” rating to a “buy” rating and upped their price target for the company from $960.00 to $1,400.00 in a research report on Wednesday, August 26th.

Institutional Investors Weigh In On argenex

Several large investors have recently modified their holdings of ARGX. Tidal Investments LLC boosted its holdings in argenex by 97.8% during the second quarter. Tidal Investments LLC now owns 2,362 shares of the company’s stock worth $2,191,000 after purchasing an additional 1,168 shares during the last quarter. Squarepoint Ops LLC raised its stake in shares of argenex by 314.8% during the 2nd quarter. Squarepoint Ops LLC now owns 58,400 shares of the company’s stock worth $54,182,000 after purchasing an additional 44,321 shares during the period. Peregrine Capital Management LLC purchased a new position in shares of argenex in the 2nd quarter worth about $27,584,000. Optiver Holding B.V. boosted its holdings in shares of argenex by 907.0% in the 1st quarter. Optiver Holding B.V. now owns 10,110 shares of the company’s stock worth $7,383,000 after buying an additional 9,106 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Price Performance

Shares of NASDAQ:ARGX opened at $930.95 on Thursday. The company has a market cap of $58.54 billion, a price-to-earnings ratio of 32.48, a PEG ratio of 0.83 and a beta of 0.48. The firm has a 50 day simple moving average of $936.34 and a 200 day simple moving average of $856.24. argenex has a one year low of $661.85 and a one year high of $1,072.75.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.44 by $0.36. The company had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. As a group, analysts expect that argenex will post 28.63 EPS for the current year.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.